Screener / SEC EDGAR /CIK 0001157601 /10-K filed Feb 19, 2026, compared with Feb 26, 2025 /Numbers from the XBRL of the 10-Ks
Nasdaq Health care · Pharmaceuticals

Madrigal Pharmaceuticals, Inc. MDGL

Compare with peers Embed
SEC comment letters, last 20 years

2 reviews of MDGL's filings by SEC staff

UPLOAD and CORRESP
Reviews 2 latest letter Nov 21, 2023
Questions asked 4 each answered in the company's own letter
No closing letter 1 reviews without a letter saying the staff completed it

When the SEC's staff reviews a filing, it writes to the company with numbered questions, and the company answers each one in a letter. SEC publishes the exchange once the review is over, at least 20 business days later. A question is not an accusation; most reviews end with the company adding detail to its next filing.

How the reviews went

Every review on EDGAR, from the first staff letter to the letter that closes it

  1. 1. Staff letters 3 UPLOAD
  2. 2. Questions in them 4 numbered comments
  3. 3. Company replies 3 CORRESP
  4. 4. Reviews closed 1 of 2 closing letter

Half the closed reviews took 65 days or less from the first letter to the closing letter.

Form 10-K

2023-11-21 to 2024-01-25 · 3 questions · 2 letters from the SEC, 2 from the company
Review closed 2024-01-25
Results discussion (MD&A)
Dual Primary Endpoints (52 Weeks) and Key Secondary Endpoint (24 weeks), page 9
SEC asked (1)
We note your disclosure on page 10 that Resmetirom was safe and well tolerated. Determinations related to safety are within the sole authority of the FDA. In future filings, please refrain from making such assessments related to product candidates that have not been approved. Additionally, please disclose all serious adverse events related to Resmetirom and disclose the number of such events.
Rest of the question

Explain how you have determined that the candidate is well tolerated when trial participants experienced serious adverse events.

MDGL answered
Madrigal acknowledges the Staff’s comment and advises the Staff that in future reports filed with the SEC, it will refrain from making express statements that resmetirom is safe pending approval by the U.S. FDA, or unless another (e.g. foreign) regulatory authority has made such a safety determination concerning resmetirom (in which case such disclosure would be limited to such context).

(b)

Madrigal acknowledges the Staff’s comment and confirms the referenced disclosure will be updated in our forthcoming Form 10-K to be filed with the SEC concerning any reportable SAE (and number)
Rest of the answer

considered related to investigational product.

(c)

Madrigal believes that the referenced disclosure is accurate that resmetirom was well tolerated since treated patients experienced only generally mild and transient diarrhea at the beginning of therapy and generally mild nausea. These are not SAEs related to resmetirom. Based on SEC positions and responses in other life science comment letters, and subject to your review, Madrigal currently plans to continue to make “well tolerated” statements in future filings.

Read in the reply
In its next report

First report after the company's reply of Dec 14, 2023: 10-K filed Feb 28, 2024 ↗, against the 10-K filed Feb 23, 2023 ↗.

Tickdelta does not hold the text of both reports, so they are not compared here.

Research and Development Expenses, page 65
SEC asked (2)
We note the statement that you expect your research and development expenses will increase substantially in the future. Accordingly for each period presented in future filings, please revise to provide a breakdown of the amount of research and development expense incurred for each of your lead product candidates by program. For product candidates with more than one application, provide a breakdown by indication.
Rest of the question

To the extent that you do not track expenses by product candidate, program, or indication, please disclose that fact and explain why you do not maintain and evaluate research and development cost in this manner. For all unallocated research and development expense, provide a breakdown by type or nature of expense such that the sum reconciles to total research and development expense for the period.

MDGL answered
The statement made concerning expected increases in future research and development expenses in the Form 10-K was accurate when made. However, for the information of the Staff, Madrigal will evaluate whether it is appropriate to include this statement (or make an adjusted statement for future R&D spend outlook) in future filings.

Madrigal wishes to advise the Staff that it has a single product candidate (resmetirom) and is seeking approval of resmetirom to treat one disease state, NASH, for which there is no currently approved therapeutic in the US or EU.
Rest of the answer

See disclosures in the Form 10-K on pages 7, 8 (clinical trials chart describing studies to support use of resmetirom to treat one disease state, NASH), 12, 13 and 64.

Since there is currently not more than one product candidate or program under clinical study for approval,

Madrigal respectfully submits that a breakdown of R&D expenses along the lines suggested in the Staff’s comment is not required. All R&D costs in the Form 10-K for the three year period ending

December 31, 2022 relate to R&D costs for resmetirom to treat NASH patients; the same is true for R&D costs reported in the first through third quarter Forms 10-Q filed during 2023.

(d)

Madrigal further confirms that it had no Unallocated R&D expenses to report in its Form 10-K and does not currently expect to have any such Unallocated R&D expenses in the future.

* * *

If the Staff should have any questions, or would like further information, concerning any of the responses above, please do not hesitate to contact the undersigned at 267 824 2827. We thank you in advance for your attention to the above.

Read in the reply
In its next report

First report after the company's reply of Dec 14, 2023: 10-K filed Feb 28, 2024 ↗, against the 10-K filed Feb 23, 2023 ↗.

Tickdelta does not hold the text of both reports, so they are not compared here.

Research and Development, page 65
SEC asked
We note your response to prior comment 2. For each period presented in your financial statements, please revise future MD&A to provide a quantified breakdown of research and development expenses by the type or nature of expense.
MDGL answered
The Company confirms that it will prepare future MD&A presentations to provide a quantitative breakdown of R&D expense components by the type or nature of expense for each period presented in such filing, consistent with Item 303(b) of Regulation S-K.

* * *

If the Staff should have any questions, concerning the responses above, please do not hesitate to contact the undersigned at 267 824 2827. We thank you in advance for your attention to this.
Read in the reply
In its next report

First report after the company's reply of Jan 17, 2024: 10-K filed Feb 28, 2024 ↗, against the 10-K filed Feb 23, 2023 ↗.

Tickdelta does not hold the text of both reports, so they are not compared here.

Also in this review: request for more time, Dec 8, 2023, closing letter, 2024-01-25

Form S-3

2013-03-18 to 2013-04-29 · 1 question · 1 letter from the SEC, 1 from the company
No closing letter
General
SEC asked
We note that your registration statement incorporates by reference materials from your Annual Report on Form 10-K for the year ended December 31, 2012. This filing does not contain the information required by Part III of Form 10-K.
Rest of the question

We will not be in a position to accelerate the effectiveness of your registration statement until you amend your Form 10-K to include the Part III information or have provided the information in a definitive proxy statement.

MDGL answered
With respect to the above-referenced Registration Statement on Form S-3 (the “Registration Statement”), and pursuant to Rule 461 of Regulation C promulgated under the Securities Act of 1933, as amended, the undersigned hereby respectfully requests, on behalf of Synta Pharmaceuticals Corp. (the “Company”), that the Securities and Exchange Commission (the “Commission”) accelerate the effective date of the Registration Statement to Wednesday, May 1, 2013 at 4:00 p.m., or as soon as practicable thereafter.

In connection with the foregoing request, the Company acknowledges the following:

·
Rest of the answer

should the Commission or the staff, acting pursuant to delegated authority, declare the filing effective, it does not foreclose the Commission from taking any action with respect to the filing;

· the action of the Commission or the staff, acting pursuant to delegated authority, in declaring the filing effective, does not relieve the Company from its full responsibility for the adequacy and accuracy of the disclosure in the filing; and

· the Company may not assert staff comments and the declaration of effectiveness as a defense in any proceeding initiated by the Commission or any person under the federal securities laws of the United States.

The cooperation of the staff in meeting the timetable described above is very much appreciated.

Read in the reply

Letters without questions

Other letters

UPLOAD and CORRESP
6 other letters: notices that a filing will not be reviewed, requests to declare a registration effective, and the like

From the SEC's correspondence on EDGAR: staff letters (form UPLOAD) and company letters (form CORRESP), 14 letters filed since 2013-03-19. Questions and answers are matched by their numbers; topics come from words in each question. The reports are compared word for word (same form, before the first SEC letter against the first report after the company's reply). No AI.

Sources

The SEC's correspondence on EDGAR: staff letters (form UPLOAD) and company letters (form CORRESP), matched question by question. No AI.

Also

Filings: the letters in the filing list.

Work with it

Excel workbook · CSV. Google Sheet that stays up to date: paste =IMPORTDATA("https://tickdelta.com/company/MDGL/export.csv") into a cell.

Next in Owners and insiders:Insider trades
Esc

Type a ticker such as AAPL, a name, an investor such as Buffett, or a topic such as tariffs. ↑ ↓ to move, Enter to open.